The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

Vaccine

Volumn 24, Issue 17, 2006, Pages 3408-3419

  Martin, Carlos ^a,g   Williams, Ann ^b   Hernandez Pando, Rogelio ^c   Cardona, Pere J ^d   Gormley, Eamonn ^e   Bordat, Yann ^f   Soto, Carlos Y ^a   Clark, Simon O ^b   Hatch, Graham J ^b   Aguilar, Diana ^c   Ausina, Vicente ^d   Gicquel, Brigitte ^f  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f INSTITUT PASTEUR   (France)

^g UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Attenuation; BCG; Live vaccine; Tuberculosis

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; PHOP PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; GENE MUTATION; GUINEA PIG; HISTOPATHOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL TIME; TUBERCULOSIS; VIRULENCE;

ANIMALS; BACTERIAL PROTEINS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GUINEA PIGS; MICE; MICE, INBRED BALB C; MICE, SCID; MUTATION; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 33645314357     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.017     Document Type: Article

References (40)

1. WHO. Global Report Tuberculosis. Global tuberculosis control - surveillance, planning, financining. World Health Organization, Geneva, 2005. http://www.who.int/tb/publications/global_report/en/index.html.
2. WHO/IUATLD. Anti-Tuberculosis Drug Resistance in the World. Report no. 3: prevalence and trends. WHO/IUATLD. Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1999-2002. World Health Organization and International Union Against Tuberculosis and Lung Disease, Geneva, 2004. http://www.who.int/ tb/publications/who_htm_tb_2004_343/en/index.html.
3. D.B. Young Building a better tuberculosis vaccine Nat Med 9 5 2003 503 504
4. P.E. Fine Variation in protection by BCG: implications of and for heterologous immunity Lancet 346 8986 1995 1339 1345
5. M.A. Behr BCG - different strains, different vaccines? Lancet Infect Dis 2 2 2002 86 92
6. A.S. Pym, P. Brodin, and L. Majlessi Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis Nat Med 9 5 2003 533 539
7. D.B. Young Current tuberculosis vaccine development Clin Infect Dis 30 Suppl. 3 2000 S254 S256
8. I.M. Orme Preclinical testing of new vaccines for tuberculosis: a comprehensive review Vaccine 24 1 2006 2 19
9. S.H. Kaufmann Is the development of a new tuberculosis vaccine possible? Nat Med 6 9 2000 955 960
10. W.J. Britton, and U. Palendira Improving vaccines against tuberculosis Immunol Cell Biol 81 1 2003 34 45
11. V. Pelicic, M. Jackson, J.M. Reyrat, W.R. Jacobs Jr., B. Gicquel, and C. Guilhot Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis Proc Natl Acad Sci U S A 94 20 1997 10955 10960
12. S. Bardarov, J. Kriakov, and C. Carriere Conditionally replicating mycobacteriophages: a system for transposon delivery to Mycobacterium tuberculosis Proc Natl Acad Sci U S A 94 20 1997 10961 10966
13. J.E. Clark-Curtiss, and S.E. Haydel Molecular genetics of Mycobacterium tuberculosis pathogenesis Annu Rev Microbiol 57 2003 517 549
14. S.T. Cole, R. Brosch, and J. Parkhill Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence Nature 393 6685 1998 537 544
15. L.R. Camacho, D. Ensergueix, E. Perez, B. Gicquel, and C. Guilhot Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis Mol Microbiol 34 2 1999 257 267
16. J.S. Cox, B. Chen, M. McNeil, and W.R. Jacobs Jr. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice Nature 402 6757 1999 79 83
17. V.K. Sambandamurthy, X. Wang, and B. Chen A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis Nat Med 8 10 2002 1171 1174
18. D.A. Smith, T. Parish, N.G. Stoker, and G.J. Bancroft Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates Infect Immun 69 2 2001 1142 1150
19. E.A. Groisman The pleiotropic two-component regulatory system PhoP-PhoQ J Bacteriol 183 6 2001 1835 1842
20. P.I. Fields, E.A. Groisman, and F. Heffron A Salmonella locus that controls resistance to microbicidal proteins from phagocytic cells Science 243 4894 Pt 1 1989 1059 1062
21. C.Y. Soto, M.C. Menendez, and E. Perez IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks J Clin Microbiol 42 1 2004 212 219
22. J. Gonzalo Asensio, C. Maia, and N.L. Ferrer The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis J Biol Chem 281 3 2006 1313 1316
23. E. Perez, S. Samper, Y. Bordas, C. Guilhot, B. Gicquel, and C. Martin An essential role for phoP in Mycobacterium tuberculosis virulence Mol Microbiol 41 1 2001 179 187
24. A.S. Pym, P. Brodin, R. Brosch, M. Huerre, and S.T. Cole Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti Mol Microbiol 46 3 2002 709 717
25. Sambrook JAR, DW. Molecular cloning a laboratory manual. New York: Cold Spring Harbor Laboratory Press; 2001.
26. A.K. Arriaga, E.H. Orozco, L.D. Aguilar, G.A. Rook, and R. Hernandez Pando Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis Clin Exp Immunol 128 2 2002 229 237
27. A. Williams, A. Davies, P.D. Marsh, M.A. Chambers, and R.G. Hewinson Comparison of the protective efficacy of bacille calmette-Guerin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis Clin Infect Dis 30 Suppl 3 2000 S299 S301
28. M.K. Hondalus, S. Bardarov, R. Russell, J. Chan, W.R. Jacobs Jr., and B.R. Bloom Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis Infect Immun 68 5 2000 2888 2898
29. M.A. Horwitz, B.W. Lee, B.J. Dillon, and G. Harth Protective immunity against tuberculosis induced by vaccination with major extra cellular proteins of Mycobacterium tuberculosis Proc Natl Acad Sci U S A 92 5 1995 1530 1534
30. S.L. Baldwin, C. D'Souza, and A.D. Roberts Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis Infect Immun 66 6 1998 2951 2959
31. M.A. Horwitz, G. Harth, B.J. Dillon, and S. Maslesa-Galic Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model Proc Natl Acad Sci U S A 97 25 2000 13853 13858
32. M.A. Behr, M.A. Wilson, and W.P. Gill Comparative genomics of BCG vaccines by whole-genome DNA microarray Science 284 5419 1999 1520 1523
33. H.J. Mollenkopf, M. Kursar, and S.H. Kaufmann Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin induce equal protection J Infect Dis 190 3 2004 588 597
34. S.L. Sampson, C.C. Dascher, and V.K. Sambandamurthy Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs Infect Immun 72 5 2004 3031 3037
35. M.A. Horwitz, and G. Harth A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis Infect Immun 71 4 2003 1672 1679
36. L. Brandt, Y.A. Skeiky, and M.R. Alderson The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs Infect Immun 72 11 2004 6622 6632
37. E.H. Wiegeshaus, D.N. McMurray, A.A. Grover, G.E. Harding, and D.W. Smith Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs Am Rev Respir Dis 102 3 1970 422 429
38. A. Williams, G.J. Hatch, and S.O. Clark Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis Tuberculosis (Edinb) 85 1-2 2005 29 38
39. H. McShane, A.A. Pathan, and C.R. Sander Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans Nat Med 10 11 2004 1240 1244
40. A.T. Kamath, U. Fruth, and M.J. Brennan New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development Vaccine 23 29 2005 3753 3761